Drug Trial Radar · NCT00978211
DOTA-TOC in Metastasized Neuroendocrine Tumors
Last checked: Nov 19, 2026Latest source record: Aug 7, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,499
Actual
Start
Sep 1997
Primary completion
Sep 2013
Study completion Dec 2013
Sponsor
- Lead sponsor
- University Hospital, Basel, SwitzerlandAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 16, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The investigators aim to explore the efficacy of \[90Y-DOTA\]-TOC and \[177LuDOTA\]-TOC therapy in advanced neuroendocrine cancer. Therefore, the investigators assess response, survival and long-term safety profile of systemic \[90Y-DOTA\]-TOC and \[177LuDOTA\]-TOC treatment in metastasized neuroendocrine cancer patients. Adverse events are assessed according to the criteria of the National Cancer Institute. Survival analyses are performed using multiple regression models.
Conditions
- Neuroendocrine Tumors
Interventions
DOTA-TOC TreatmentDrug
Intravenous injections of DOTA-TOC. Repeated treatment cycles for responders, except in case of * renal toxicity * loss of patient transferability or * denial of further treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- ResponseTime frame: 3 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospital
Basel, Canton of Basel-City, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.